| Autor: |
Volpi CC; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pietrantonio F; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Faculty of Medicine, Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy., Gloghini A; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Fucà G; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Giordano S; Department of Oncology, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO - IRCCS - Candiolo (TO), Turin, Italy., Corso S; Department of Oncology, University of Turin, Turin, Italy.; Candiolo Cancer Institute, FPO - IRCCS - Candiolo (TO), Turin, Italy., Pruneri G; Department of the Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Antista M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cremolini C; Unit of Medical Oncology, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy., Fasano E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Saggio S; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Bartolomeo M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., de Braud F; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Faculty of Medicine, Oncology and Hemato-Oncology Department, Università degli Studi di Milano, Milan, Italy., Di Nicola M; Department of Oncology and Hemato-oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. serenella.pupa@istitutotumori.mi.it., Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. |
| Abstrakt: |
The HER2 splice variant characterized by the deletion of exon 16 and denominated as d16HER2, is associated with HER2-positive breast cancer (BC) aggressiveness, stemness, and trastuzumab susceptibility and is considered to be a "flag" of HER2 dependence. However, with the exception of quantitative real-time PCR analysis, easily reproducible assays are still lacking to clinically detect and quantify the d16HER2 expression. Further, no data on d16HER2 expression and its potential role are available in HER2-positive gastrointestinal malignancies. Here, we used a novel RNA in situ hybridization technique (BaseScope) to discriminate d16HER2 variant expression from the wild type isoform (WTHER2) and to assess their levels across different HER2-positive histological samples. Our results demonstrate the existence of outliers, with d16HER2 mRNA high scores restricted to HER2-positive gastric cancer (GC) and colorectal cancer (CRC) coupled with increased d16HER2 expression compared with BC. Consistent with previously reported data on BC, experiments performed in HER2-positive GC patient-derived xenografts suggest that increased d16HER2 expression is associated with a clinical benefit/response to single-agent trastuzumab. Therefore, d16HER2 may be considered as a "flag" of HER2 dependence in GC and can be clinically investigated as a marker of trastuzumab susceptibility in several other HER2-driven cancers, including CRC. As a clinical proof-of-concept, we indicate that high d16HER2 mRNA scores are exclusively found in patients with a long-term benefit from trastuzumab exceeding 12 months (clinical "outliers"), and that d16HER2 expression is also increased in circulating tumor-released exosomes obtained from baseline plasma samples of long-term responders. |
